IMMUNITYBIO, INC. Available-for-sale Securities, Gross Realized Gain (Loss)
IMMUNITYBIO, INC. (IBRX) reported Available-for-sale Securities, Gross Realized Gain (Loss) of -$9.00 thousand for the 12-month period ending 2020-12-31, per its 8-K/A filed 2021-04-22.
Discontinued › Income Statement › Other Income
us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet · last filed 2021-04-22
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2019-09-30 was -$4.00K.
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-12-31 was $1.00K, a 85.71% decline year-over-year.
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2018 was $3.00K, a 91.89% decline from fiscal 2017.
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2017 was $37.00K, a 66.67% decline from fiscal 2016.
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2016 was $111.00K, a 95.56% decline from fiscal 2015.
- IMMUNITYBIO, INC. available-for-sale securities, gross realized gain (loss) for fiscal 2015 was $2.50M.
| Period end | Available-for-sale Securities, Gross Realized Gain (Loss) 3 month | Available-for-sale Securities, Gross Realized Gain (Loss) 6 month | Available-for-sale Securities, Gross Realized Gain (Loss) 9 month | Available-for-sale Securities, Gross Realized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2020-12-31 | -$9.00K 8-K/A · filed 2021-04-22 | |||
| 2019-12-31 | $0.00 derived: 8-K/A 12 month − 10-Q 9 month · filed 2021-04-22 | -$4.00K derived: sum of 2 quarters · filed 2021-04-22 | -$4.00K 8-K/A · filed 2021-04-22 | |
| 2019-09-30 | -$4.00K 10-Q · filed 2019-11-05 | -$4.00K 10-Q · filed 2019-11-05 | ||
| 2018-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | $1.00K derived: sum of 2 quarters · filed 2021-03-04 | $1.00K derived: sum of 3 quarters · filed 2021-03-04 | $3.00K 10-K · filed 2021-03-04 |
| 2018-09-30 | $0.00 10-Q · filed 2019-11-05 | $0.00 derived: sum of 2 quarters · filed 2019-11-05 | $2.00K 10-Q · filed 2019-11-05 | $9.00K derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-06-30 | $0.00 10-Q · filed 2018-08-06 | $2.00K 10-Q · filed 2018-08-06 | $9.00K derived: sum of 3 quarters · filed 2020-03-25 | $43.00K derived: sum of 4 quarters · filed 2020-03-25 |
| 2018-03-31 | $2.00K 10-Q · filed 2018-05-07 | $9.00K derived: sum of 2 quarters · filed 2020-03-25 | $43.00K derived: sum of 3 quarters · filed 2020-03-25 | $42.00K derived: sum of 4 quarters · filed 2020-03-25 |
| 2017-12-31 | $7.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-25 | $41.00K derived: sum of 2 quarters · filed 2020-03-25 | $40.00K derived: sum of 3 quarters · filed 2020-03-25 | $37.00K 10-K · filed 2020-03-25 |
| 2017-09-30 | $34.00K 10-Q · filed 2018-11-07 | $33.00K derived: sum of 2 quarters · filed 2018-11-07 | $30.00K 10-Q · filed 2018-11-07 | $74.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-06-30 | -$1.00K 10-Q · filed 2018-08-06 | -$4.00K 10-Q · filed 2018-08-06 | $40.00K derived: sum of 3 quarters · filed 2019-03-13 | $89.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2017-03-31 | -$3.00K 10-Q · filed 2018-05-07 | $41.00K derived: sum of 2 quarters · filed 2019-03-13 | $90.00K derived: sum of 3 quarters · filed 2019-03-13 | $106.00K derived: sum of 4 quarters · filed 2019-03-13 |
| 2016-12-31 | $44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-13 | $93.00K derived: sum of 2 quarters · filed 2019-03-13 | $109.00K derived: sum of 3 quarters · filed 2019-03-13 | $111.00K 10-K · filed 2019-03-13 |
| 2016-09-30 | $49.00K 10-Q · filed 2017-11-07 | $65.00K derived: sum of 2 quarters · filed 2017-11-07 | $67.00K 10-Q · filed 2017-11-07 | |
| 2016-06-30 | $16.00K 10-Q · filed 2017-08-07 | $18.00K 10-Q · filed 2017-08-07 | ||
| 2016-03-31 | $1.00K 10-Q · filed 2017-05-08 | |||
| 2015-12-31 | $2.50M 10-K · filed 2018-03-12 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |